Invus L.P. Amends Lexicon Pharmaceuticals Stake

TL;DR

Invus L.P. updated its Lexicon Pharma stake filing - watch for more moves.

AI Summary

On May 14, 2024, Invus, L.P. filed an amendment to its Schedule 13D, disclosing its beneficial ownership of Lexicon Pharmaceuticals, Inc. The filing indicates a change in the reporting person's holdings, though specific new dollar amounts or exact share counts are not detailed in this excerpt. The filing is an amendment, suggesting ongoing activity or adjustments to their investment strategy.

Why It Matters

This amendment signals potential shifts in significant shareholder positions, which could influence Lexicon Pharmaceuticals' stock performance and strategic direction.

Risk Assessment

Risk Level: medium — Schedule 13D filings often indicate significant investor activity, which can lead to volatility and strategic changes for the company.

Key Players & Entities

• Invus, L.P. (company) — Reporting person filing amendment
• Lexicon Pharmaceuticals, Inc. (company) — Subject company
• ARTAL GROUP S.A. (company) — Group member
• MR. AMAURY WITTOUCK (person) — Group member
• MR. RAYMOND DEBBANE (person) — Group member

FAQ

Key Financial Figures

• $0.001 — me of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securiti

Filing Documents

• d839722dsc13da.htm (SC 13D/A) — 211KB
• 0001193125-24-138357.txt ( ) — 214KB

of the Statement is hereby amended and supplemented as follows

Item 4 of the Statement is hereby amended and supplemented as follows : As previously disclosed in Amendment No. 21, on March 13, 2024, Artal International S.C.A. acquired 1,150,922 shares of Preferred Stock. Each share of Preferred Stock would automatically convert into 50 shares (subject to adjustments) of Issuer Common Stock immediately following the satisfaction of all of the following conditions: (i) the approval of the New Charter by the shareholders of the Issuer at the Annual Meeting; (ii) the adoption of the New Charter by the Issuers board of directors; and (iii) the filing and acceptance of the New Charter with and by the Secretary of State of the State of Delaware. On May 10, 2024, all conditions were met, and the 1,150,922 shares of Preferred Stock directly held by Artal International S.C.A. automatically converted into 57,546,100 shares of Issuer Common Stock. Item5. Interest in Securities of the Issuer Items 5(a)-(c) of the Statement are hereby amended and restated in their entirety as follows: The information contained in rows 7, 8, 9, 10, 11 and 13 on each of the cover pages of this Schedule 13D and the information set forth or incorporated in Items 2, 3 and 6 is incorporated by reference in its entirety into this Item 5. (a)-(b) Invus Public Equities, L.P. is the record and beneficial owner of 3,516,214 shares of Issuer Common Stock, representing approximately 1.0% of the outstanding shares of Issuer Common Stock. Invus Public Equities Advisors, LLC, as the general partner of Invus Public Equities, L.P., controls Invus Public Equities, L.P. and, accordingly, may be deemed to beneficially own the shares of Issuer Common Stock held by Invus Public Equities, L.P. The Geneva branch of Artal International S.C.A., as the managing member of Invus Public Equities Advisors, LLC, controls Invus Public Equities Advisors, LLC and, accordingly, may be deemed to beneficially own the shares of Issuer Common Stock that Invus Public Equities Advisors, LLC